艾迪药业: management transactions · France · AMF SSE:688488 FR FR · AMF Mcap 6.9Bn€
Browse the full directors' dealings record of 艾迪药业, a listed equity based in France. Shares trade on FR FR, under the oversight of AMF. Market capitalisation: €6.9bn. The latest transaction was filed on 9 March 2026 — Purchase. Among the most active insiders: 傅和亮. All data is accessible without an account.
Financial data FY ended December 2025 · cache
Income statement
Revenue 719.2 M€
Gross profit 480.4 M€ 67% margin
Net income −19.5 M€ -2.7% margin
Balance sheet & cash
Market cap 6.87 Bn€
Total debt 559.2 M€
Free Cash Flow −30.3 M€
Last declaration on 9 March 2026
Declarations 11 total
Executives ● Purchase18 SSE
68,800 shares
SSE:273000000236276600 · 9 Mar 2026
Ideal exit: 4 Dec 2026 (T+270) Executives ● Purchase18 SSE
53,079 shares
SSE:273000000231957980 · 5 Mar 2026
Ideal exit: 30 Nov 2026 (T+270) Executives ● Purchase18 SSE
133,070 shares
SSE:273000000227204130 · 4 Mar 2026
Ideal exit: 29 Nov 2026 (T+270) Executives ● Sale14 SSE
107,718 shares
SSE:173000008167046720 · 22 Oct 2024
Executives ● Purchase18 SSE
100,000 shares
SSE:173000007827567680 · 9 Jul 2024
Ideal exit: 5 Apr 2025 (T+270) Executives ● Purchase14 SSE
146,400 shares
SSE:173000007815776060 · 4 Jul 2024
Ideal exit: 31 Mar 2025 (T+270) Executives ● Purchase14 SSE
200,000 shares
SSE:173000007270051780 · 22 Jan 2024
Ideal exit: 18 Oct 2024 (T+270) Executives ● Purchase14 SSE
200,000 shares
SSE:173000007054153300 · 1 Nov 2023
Ideal exit: 28 Jul 2024 (T+270) Executives ● Purchase7 SSE
189,700 shares
SSE:173000007054153250 · 31 Oct 2023
Ideal exit: 27 Jul 2024 (T+270) Executives ● Purchase14 SSE
68,319 shares
SSE:173000006953582370 · 20 Sept 2023
Ideal exit: 16 Jun 2024 (T+270) Executives ● Purchase7 SSE
61,000 shares
SSE:173000005549941020 · 25 May 2022
Ideal exit: 19 Feb 2023 (T+270)
